Caucasian women overestimate their risk of breast cancer while African American and Hispanic women underestimate their risk, according to research presented at BCS 2013.
A survey presented at BCS 2013 has found a number of factors that cause rural US women to avoid breast cancer screening.
The benefit of perioperative MRI for women with ductal carcinoma in situ (DCIS) is "uncertain," found a study presented during BCS 2013.
ChemotherapyAdvisor.com Editorial Board member Dr. Edith Perez of the Mayo Clinic, Jacksonville, FL, recommends high impact abstracts at the Breast Cancer Symposium 2013.
Women who underwent radiation for ductal carcinoma in situ do not face an increased risk of cardiovascular disease, found a study presented at BCS 2013.
Workshops with patient advocates are a promising approach to identifying meaningful patient-reported outcome end points for clinical studies of breast cancer treatments, found research at BCS 2013.
Eribulin safety and time to treatment failure in real-world clinical settings are comparable to those identified in previous clinical trials, found a study presented at BCS 2013.
T-DM1 is as safe and effective in previously treated patients with HER2+ metastatic breast cancer in clinical settings as it was in clinical trials, found research at BCS 2013.
Most patients would prefer to receive assessments, support during follow-up appoints, but details of their preferences after treatment vary, found data presented at BCS 2013.
Weight gain during chemotherapy is associated with premenopausal status but not patient age, tumor histology or stage, or therapeutic regimens, found research at BCS 2013.
Survivors of breast cancer prefer a one-on-one consultation with a clinician followed by topic-specific online webinars that include live Q&A sessions, found research presented at BCS 2013.
Genome-wide microarray analyses of copy number variation and gene expression found two dysregulated functions in inflammatory breast cancer, found a study at BCS 2013.
dtectDx™ Breast Assay Plus Standard of Care Improves Breast Cancer Detection in Women Younger than 50September 05, 2013
Combined with standard of care, the dtectDx Breast test is most effective at detecting breast cancer in women age 50 or younger, found data presented at BCS 2013.
Bioelectrical impedance analysis misses 20% of true lymphedema cases, but was reliable in survivors with lymphedema, according to data presented at BCS 2013.
Women who underwent unilateral or contralateral prophylactic mastectomy instead of breast-conserving surgery felt they were "taking control of cancer", found research presented at BCS 2013.
Ductal not otherwise specified carcinomas account for 81.8% of ER-positive breast cancer cases, found a study presented at BCS 2013.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma